DPP-4 inhibitor dose selection according to manufacturer specifications: A contemporary experience from UK general practice

Dionysis Spanopoulos; Michael Busse; Joanne Webb; Abigail Tebboth; Nicholas D. Gollop; Michael W. Marcus

doi:10.1016/j.clinthera.2019.05.010

DPP-4 inhibitor dose selection according to manufacturer specifications: A contemporary experience from UK general practice

Dionysis Spanopoulos, Michael Busse, Joanne Webb, Abigail Tebboth, Nicholas D. Gollop, Michael W. Marcus

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

20 Downloads (Pure)

Abstract

Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. This cross-sectional study examines all DPP-4 inhibitor initiations that require dose adjustment and the dose selection using data from UK general practice. Results indicate that 34% of patients taking a nonlinagliptin DPP-4 inhibitor were given a higher dose and 11% a lower dose than specified in the Summary of Product Characteristics. This reinforces the deviation from Summary of Product Characteristics prescription of DPP-4 inhibitors identified in earlier studies despite improvement in compatibility with routine reporting. (C) 2019 The Authors. Published by Elsevier Inc.

Original language	English
Pages (from-to)	1622-1630
Number of pages	9
Journal	Clinical Therapeutics
Volume	41
Issue number	8
Early online date	1 Jun 2019
DOIs	https://doi.org/10.1016/j.clinthera.2019.05.010
Publication status	Published - Aug 2019
Externally published	Yes

Keywords

dose selection
DPP-4 inhibitors
summary of product characteristics
renal impairment
Type 2 diabetes mellitus
UK general practice
TYPE-2 DIABETES-MELLITUS
PEPTIDASE 4 INHIBITORS

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clinthera.2019.05.010Licence: CC BY-NC-ND

Published_VersionFinal published version, 461 KBLicence: CC BY-NC-ND

Cite this

@article{1a6d81e679984da494b7abd349ba4cae,

title = "DPP-4 inhibitor dose selection according to manufacturer specifications: A contemporary experience from UK general practice",

abstract = "Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. This cross-sectional study examines all DPP-4 inhibitor initiations that require dose adjustment and the dose selection using data from UK general practice. Results indicate that 34% of patients taking a nonlinagliptin DPP-4 inhibitor were given a higher dose and 11% a lower dose than specified in the Summary of Product Characteristics. This reinforces the deviation from Summary of Product Characteristics prescription of DPP-4 inhibitors identified in earlier studies despite improvement in compatibility with routine reporting. (C) 2019 The Authors. Published by Elsevier Inc.",

keywords = "dose selection, DPP-4 inhibitors, summary of product characteristics, renal impairment, Type 2 diabetes mellitus, UK general practice, TYPE-2 DIABETES-MELLITUS, PEPTIDASE 4 INHIBITORS",

author = "Dionysis Spanopoulos and Michael Busse and Joanne Webb and Abigail Tebboth and Gollop, {Nicholas D.} and Marcus, {Michael W.}",

year = "2019",

month = aug,

doi = "10.1016/j.clinthera.2019.05.010",

language = "English",

volume = "41",

pages = "1622--1630",

journal = "Clinical Therapeutics",

issn = "0149-2918",

publisher = "Excerpta Medica",

number = "8",

}

DPP-4 inhibitor dose selection according to manufacturer specifications: A contemporary experience from UK general practice. / Spanopoulos, Dionysis; Busse, Michael; Webb, Joanne; Tebboth, Abigail; Gollop, Nicholas D.; Marcus, Michael W.

In: Clinical Therapeutics, Vol. 41, No. 8, 08.2019, p. 1622-1630.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - DPP-4 inhibitor dose selection according to manufacturer specifications: A contemporary experience from UK general practice

AU - Spanopoulos, Dionysis

AU - Busse, Michael

AU - Webb, Joanne

AU - Tebboth, Abigail

AU - Gollop, Nicholas D.

AU - Marcus, Michael W.

PY - 2019/8

Y1 - 2019/8

N2 - Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. This cross-sectional study examines all DPP-4 inhibitor initiations that require dose adjustment and the dose selection using data from UK general practice. Results indicate that 34% of patients taking a nonlinagliptin DPP-4 inhibitor were given a higher dose and 11% a lower dose than specified in the Summary of Product Characteristics. This reinforces the deviation from Summary of Product Characteristics prescription of DPP-4 inhibitors identified in earlier studies despite improvement in compatibility with routine reporting. (C) 2019 The Authors. Published by Elsevier Inc.

AB - Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. This cross-sectional study examines all DPP-4 inhibitor initiations that require dose adjustment and the dose selection using data from UK general practice. Results indicate that 34% of patients taking a nonlinagliptin DPP-4 inhibitor were given a higher dose and 11% a lower dose than specified in the Summary of Product Characteristics. This reinforces the deviation from Summary of Product Characteristics prescription of DPP-4 inhibitors identified in earlier studies despite improvement in compatibility with routine reporting. (C) 2019 The Authors. Published by Elsevier Inc.

KW - dose selection

KW - DPP-4 inhibitors

KW - summary of product characteristics

KW - renal impairment

KW - Type 2 diabetes mellitus

KW - UK general practice

KW - TYPE-2 DIABETES-MELLITUS

KW - PEPTIDASE 4 INHIBITORS

U2 - 10.1016/j.clinthera.2019.05.010

DO - 10.1016/j.clinthera.2019.05.010

M3 - Article

VL - 41

SP - 1622

EP - 1630

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 8

ER -